SEATTLE--(BUSINESS WIRE)--Pacific Biometrics, Inc. (PBI) (OTCBB:PBME) announces the launch of Clinical Biomarker Services, a new area of specialty testing services for clinical drug development. Designed primarily to support clinical development of biotherapeutics, the new services will include validation of ligand-binding assays for immunogenicity testing and novel biomarkers in a regulatory-compliant laboratory environment. These new specialty biomarker services will be supported by investments in new instrument platforms for electrochemiluminescence- and multiplex-based testing.
